Seamus Fernandez
Stock Analyst at Guggenheim
(4.17)
# 439
Out of 4,893 analysts
103
Total ratings
54.17%
Success rate
13.96%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Reiterates: Buy | $116 | $38.57 | +200.75% | 8 | Jul 2, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $50 → $68 | $50.88 | +33.65% | 4 | Jun 24, 2025 | |
| AMLX Amylyx Pharmaceuticals | Initiates: Buy | $17 | $7.39 | +130.04% | 1 | Jun 24, 2025 | |
| LLY Eli Lilly and Company | Reiterates: Buy | $936 | $790.65 | +18.38% | 16 | Jun 20, 2025 | |
| MBX MBX Biosciences | Reiterates: Buy | $44 | $12.39 | +255.13% | 2 | Apr 10, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $15.27 | - | 3 | Apr 3, 2025 | |
| VERV Verve Therapeutics | Reiterates: Buy | n/a | $11.06 | - | 2 | Mar 25, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $36.26 | +341.26% | 4 | Mar 12, 2025 | |
| MTSR Metsera | Initiates: Buy | $56 | $36.41 | +53.80% | 1 | Feb 25, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | n/a | $14.63 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $137 → $130 | $84.02 | +54.73% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $39.58 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $89.04 | -21.38% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.82 | +174.91% | 1 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.11 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.40 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $14.48 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $18.90 | +164.55% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $48.52 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $71.01 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $123.73 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.22 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $1.59 | +3,296.23% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $22.68 | +98.41% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $71.81 | -47.08% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $25.78 | +47.40% | 3 | Jan 31, 2018 |
Apogee Therapeutics
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $38.57
Upside: +200.75%
Cidara Therapeutics
Jun 24, 2025
Maintains: Buy
Price Target: $50 → $68
Current: $50.88
Upside: +33.65%
Amylyx Pharmaceuticals
Jun 24, 2025
Initiates: Buy
Price Target: $17
Current: $7.39
Upside: +130.04%
Eli Lilly and Company
Jun 20, 2025
Reiterates: Buy
Price Target: $936
Current: $790.65
Upside: +18.38%
MBX Biosciences
Apr 10, 2025
Reiterates: Buy
Price Target: $44
Current: $12.39
Upside: +255.13%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $15.27
Upside: -
Verve Therapeutics
Mar 25, 2025
Reiterates: Buy
Price Target: n/a
Current: $11.06
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $36.26
Upside: +341.26%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $36.41
Upside: +53.80%
Mineralys Therapeutics
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $14.63
Upside: -
Nov 6, 2024
Maintains: Buy
Price Target: $137 → $130
Current: $84.02
Upside: +54.73%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $39.58
Upside: -
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $89.04
Upside: -21.38%
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $5.82
Upside: +174.91%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.11
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.40
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $14.48
Upside: -
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $18.90
Upside: +164.55%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $48.52
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $71.01
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $123.73
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.22
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $1.59
Upside: +3,296.23%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $22.68
Upside: +98.41%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $71.81
Upside: -47.08%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $25.78
Upside: +47.40%